再鼎医药2025年业绩前瞻：短期商业化增速放缓；双引擎助力实现长期全球价值

Investment Rating - The report maintains an "Outperform" rating for Zai Lab with a target price of HKD 35.25, while the current price is HKD 13.82 [2][10]. Core Insights - Zai Lab is expected to achieve product net revenue of USD 465 million in FY25, representing a year-on-year growth of 16.5%. The core product efgartigimod is projected to generate USD 97.96 million, with a gross profit margin of 61.0% [3][16]. - The management has reaffirmed a dual-engine strategy focusing on introducing high-quality overseas products for commercialization in China and leveraging a cross-border R&D platform for efficient global market development [4][17]. - Despite a downward revision in revenue guidance for 2025 and a delay in profitability targets, the company has a robust portfolio with eight products approved in China and several differentiated global assets in its pipeline [4][17]. Financial Performance - Revenue forecasts for FY25, FY26, and FY27 have been adjusted to USD 465 million, USD 501 million, and USD 717 million, respectively. Net loss forecasts for the same periods are revised to USD 180 million, USD 159 million, and USD 55 million [10][19]. - R&D expenses are expected to be USD 205 million, a decrease of 12.8% year-on-year, while SG&A expenses are projected at USD 284 million, down 5.0% [3][16]. Clinical Development Pipeline - Zocilurtatug (DLL3 ADC) is set to initiate three registrational clinical trials by the end of 2026, targeting small cell lung cancer and neuroendocrine carcinoma [5][21]. - Several early-stage products, including ZL-1503, ZL-6201, ZL-1222, and ZL-1311, are expected to contribute to long-term global value creation [6][9][21].